KRAS and neoplasm: Of the 14 cases, 8/14 (57 %) exhibited KRAS (exon 2, codon 12 or 13) mutations in the primary tumour and 1/14 (7 %) a NRAS (exon 3, codon 61) mutation (Table 3).